Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Finished Goods (2017 - 2025)

Neurocrine Biosciences' Finished Goods history spans 9 years, with the latest figure at $13.6 million for Q1 2025.

  • For Q1 2025, Finished Goods rose 81.33% year-over-year to $13.6 million; the TTM value through Mar 2025 reached $13.6 million, up 81.33%, while the annual FY2024 figure was $12.8 million, 4.07% up from the prior year.
  • Finished Goods reached $13.6 million in Q1 2025 per NBIX's latest filing, up from $12.8 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $17.5 million in Q4 2022 to a low of $7.5 million in Q1 2024.
  • Average Finished Goods over 5 years is $12.7 million, with a median of $12.5 million recorded in 2023.
  • Peak YoY movement for Finished Goods: dropped 29.71% in 2023, then skyrocketed 81.33% in 2025.
  • A 5-year view of Finished Goods shows it stood at $15.7 million in 2021, then grew by 11.46% to $17.5 million in 2022, then decreased by 29.71% to $12.3 million in 2023, then increased by 4.07% to $12.8 million in 2024, then grew by 6.25% to $13.6 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Finished Goods are $13.6 million (Q1 2025), $12.8 million (Q4 2024), and $11.5 million (Q3 2024).